Directly from Japan: ctDNA-Based Detection of Residual Disease Prognostic for Resected CRC
For patients with radically resected, stage II to IV colorectal cancer (CRC), circulating tumor (ct)DNA-based detection of molecular residual disease (MRD) in response to adjuvant chemotherapy (ACT) is prognostic of outcomes, according to a study presented at the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan. 18 to 20 in San Francisco.
Hiroki Yukami, M.D., Ph.D., from the Osaka Medical and Pharmaceutical University in Takatsuki, Japan, and colleagues used a personalized, tumor-informed assay for the detection and quantification of ctDNA in serial plasma samples collected after surgery in patients with radically resected, stage II to IV CRC to examine the correlation of ctDNA dynamics with outcomes. Patients underwent treatment with adjuvant chemotherapy (ACT; 1,000 patients) or observation (1,518 patients) after curative-intent surgery. The primary end point was disease-free survival.
Source: Advances and More licensed by HealthDay
